FDA approves blockbuster Dupixent extension for treatment of patients aged 12-17 with severe asexual dermatitis

amyritis, also known as eczema, is a common chronic inflammatory skin diseaseIts clinical symptoms include dry skin, redness and itchingA rash in patients with moderate lytosis may cover most of the body's skin, leading to severe, persistent itchingSevere itching can be a heavy burden on the patientToday, the U.Sfda(http:// announcedthat it has approved the extension of dupixent, a heavy-duty drug developed jointly by Regeneron Pharmaceuticals(http://and Sanofi, to treat patients between the ages of 12 and 17 with severe asexual itistThe symptoms of these patients were not fully controlled after receiving prescription treatment for external use, or they were not suitable for the use of topical medicationsDupixent can be used as a single-drug therapy or in combination with external corticosteroidsIt is estimated that the number of adolescent patients with isotrophic dermatitis is half that of adult patients, and this approval means that the number of patients treated with acursion in Dupixent has increased by 50 per centAbout Dupixent
Dupixent is a targeted biologicthe that inhibits both IL-4 and IL-13 signaling pathwaysIL-4 and IL-13 play a key role in type 2 inflammatory responses, which are important mechanisms for leading to adhesion dermatitis and other severe allergic diseasesDupixent has received FDA approval to treat adult patients with severe dermatitisIt has been approved by the FDA for breakthrough therapy for the treatment of adolescent patients with severe dermatitisThis approval is based on Dupixent's performance in the critical Phase 3 ClinicalTrial(http://, and after 16 weeks of treatment, the average improvement in eczema area and severe index (EASI) compared to baseline in patients in the Dupixent treatment group was 66% compared to baseline and 24% in the control groupThe number of patients treated with Dupixent for skin symptoms disappeared completely or almost completely more than 10 times in the control groupDupixent therapy also significantly reduced the patient's itching symptoms, and the number of patients with itching symptoms significantly reduced was 7 times that of the control group